When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is ...

Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO ...

LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

The Anglo-Swedish pharmaceutical giant AstraZeneca faces mounting pressure from shareholders regarding ongoing investigations in China, one of its key markets. The concerns emerged after the detention ...

AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

Donald Trump has been sworn in as the 47th President of the United States, completing perhaps the most remarkable political comeback in American history. The Republican, the first convicted felon ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

executive vice president of AstraZeneca's oncology hematology business unit.

AstraZeneca ranked second across the Middle East, demonstrating sustained recognition of its workplace culture and reinforcing its position as an employer of choice in the region. In a statement from ...

1 According to AstraZeneca, approval was based on results from the DESTINY ... global head, oncology business, president, CEO, Daiichi Sankyo, in the press release. 1. Enhertu approved in the US as ...